1. Home
  2. RNA

as of 12-24-2025 12:46pm EST

$72.19
+$0.05
+0.06%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 4.0B IPO Year: 2020
Target Price: $69.26 AVG Volume (30 days): 2.3M
Analyst Decision: Buy Number of Analysts: 20
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.19 EPS Growth: N/A
52 Week Low/High: $21.51 - $72.61 Next Earning Date: 11-10-2025
Revenue: $20,868,000 Revenue Growth: 106.27%
Revenue Growth (this year): 64.11% Revenue Growth (next year): 37.25%

AI-Powered RNA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 72.85%
72.85%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)

McCarthy Teresa

Chief Human Resources Officer

Sell
RNA Oct 15, 2025

Avg Cost/Share

$50.15

Shares

20,000

Total Value

$1,003,058.00

Owned After

97,130

SEC Form 4

Mosbrooker Eric

Chief Commercial Officer

Sell
RNA Oct 3, 2025

Avg Cost/Share

$45.38

Shares

6,562

Total Value

$297,771.09

Owned After

55,000

SEC Form 4

Share on Social Networks: